
2019 Sponsors
Sponsored Presentations
September 23, 2019
12:30–13:30
Anabios
Room 119
Higher Throughput Human Cardiomyocyte Assay for Safety Screening
Dr. Najah Abi-Gerges will present data from AnaBios’ unique human primary cardiomyocyte assay. AnaBios recovers high-quality cardiomyocytes for assessing drug-induced cardiotoxicity. By leveraging new technologies for higher-throughput screening, AnaBios can now support medicinal chemistry early discovery efforts with rapid turnaround and data that are highly predictive of human safety risk.
September 24, 2019
07:00–08:00
Axion BioSystems
Room 119
Maturation of iPSC-CM Function for Improved Predictivity of In Vitro CM-MEA Assays
iPSC-CMs have significantly advanced in vitro assays for cardiac safety, but remain an immature representation of the human heart. In this seminar, attendees will learn how to mature cardiomyocytes for use in functional assays of the action potential, conduction, and contractility.
12:30–13:30
Emka Technologies
Room 121
Leveraging Machine Learning for Automated ECG and Hemodynamic Analyses
Cardiovascular safety scientists are using analysis software designed to streamline the evaluation of ECG and hemodynamic endpoints. While they increase efficiency, the need to evaluate larger datasets, with increased depth brings a significant level of human intervention and processing time, with inter-user variability. This study leverages historical data to guide a novel pattern recognition algorithm in performing automated cardiovascular analyses.
12:30–13:30
Nanion Technologies
Room 119
Future Technologies in Safety Pharmacology and Drug Discovery
Session focuses on HTS approaches for studying cardiac ion channels and iPSC-CMs in research, screening, and risk assessment. We will introduce recent iPSC-CMs maturation strategies such as recordings on flexible membranes, electrical stimulation and IK1 simulation during automated patch clamp recordings. CiPA conform best practices and progress for drug development will also be presented.
12:30–13:30
TARA Biosystems
Room 120
Using hiPSC-derived Tissues for Cardiac Risk Assessment: Translational Considerations
Translational fidelity is a key consideration when selecting the appropriate model for cardiac risk assessment. Such fidelity requires a platform that reproducibly recapitulates key structural and functional features of adult human cardiac tissue. We will discuss data demonstrating the translational relevance of TARA's in vitro iPSC-derived Cardiotype tissues.
18:00–19:00
ACEA Biosciences, Inc. - A part of Agilent
Room 119
Are Functionally Mature hiPSC-Cardiomyocytes More Predictive for Safety Assessment?
As the field determines how to improve the predictivity of cardiomyocyte models, the questions being raised are: What constitutes CM maturation and is it more a predictive model? To address these questions, we explored the role of electrical pacing using ACEA's high-throughput ePacer platform and retested a subset of Phase II CiPA compounds. We will discuss our results in this presentation.
18:00–19:00
ERBC
Room 120
Arrhythmic Risk Assessment: New Biomarkers for an Improved Translation from Preclinical QT Studies to Human
We recently published several translational studies demonstrating that increases in beat to beat variability of ventricular repolarization induced by torsadogenic drugs was related to a co-activation of both sympathetic and parasympathetic nervous systems. We derived several new biomarkers with promising sensitivity and specificity reflecting a risk of autonomic conflict, this latter concept being known to trigger torsades de pointes in LQT syndromes.
September 25, 2019
12:30–13:30
Data Sciences International
Room 120
Take a Deep Breath and Relax with Impedance on Your Side
Cardiopulmonary monitoring across non-rodent species is part of the modern safety pharmacology toolbox when assessing organ system interactions. Specificity and differences will be overviewed with data from canines, NHPs and minipigs. Digital data acquisition and animal welfare will also be explored. The session is built with ample time for an open discussion on applications and experience.
12:30–13:30
NanoSurface Biomedical
Room 119
Leveraging Structurally Matured iPSC-derived Cardiomyocytes for Predictive High-throughput Screening
iPSC-CMs hold great potential for assessing various cardiotoxicity mechanisms in vitro; however their full potential is limited by their expression of fetal and embryonic phenotypes. Learn how structural maturation can improve the predictive power of these cells in a variety of cell-based assays, and how this approach can be easily integrated into most industry-standard high-throughput assays.
12:30–13:30
NMI TT Pharmaservices
Room 121
hiPSC for Drug Development and Safety Assessment Using Live Kinetic and Electrophysiological Readout
Attend to learn how drug discovery challenges are being reduced by using iPSC-derived cardiomyocytes and 3D-neural spheroids with real-time, high-throughput functional methodologies to identify potential drug-induced effects and improve predictivity. The solutions will be presented by Udo Kraushaar from NMI and guest speakers Blake Anson from StemoniX and Stephane Bedut from E-physervices.
Sponsorship Opportunities
Corporate Sponsorships
With higher levels of sponsorship comes greater exposure. There are five levels of sponsorship available:
Sponsorship at this level requires a $15,000 contribution.
• Ability to host a Sponsored Presentation
• Company Name listed and logo displayed in Mobile App
• Company Name displayed in the General Session
• Company Name listed in the printed Program
• Company Name listed in pre-meeting promotional pieces
• Company Name on the Meeting website
• Verbal acknowledgment at the Plenary Lecture
• Verbal acknowledgment at the Awards Ceremony
• Acknowledgment on a meter board at the Annual Meeting
• Sponsor badge ribbon/s for your representatives
Sponsorship at this level requires a $10,000 contribution.
• Ability to host a Sponsored Presentation
• Company Name listed and logo displayed in Mobile App
• Company Name displayed in the General Sessions
• Company Name listed in the printed Program
• Company Name listed in pre-meeting promotional pieces
• Company Name on the Meeting website
• Verbal acknowledgment at the Plenary Lecture
• Verbal acknowledgment at the Awards Ceremony
• Acknowledgment on a meter board at the Annual Meeting
• Sponsor badge ribbon/s for your representatives
Sponsorship at this level requires a $6,000 contribution.
• Ability to host a Sponsored Presentation
• Company Name listed and logo displayed in Mobile App
• Company Name displayed in the General Sessions
• Company Name listed in the printed Program
• Company Name listed in pre-meeting promotional pieces
• Company Name on the Meeting website
• Verbal acknowledgment at the Plenary Lecture
• Verbal acknowledgment at the Awards Ceremony
• Acknowledgment on a meter board at the Annual Meeting
• Sponsor badge ribbon/s for your representatives
Sponsorship at this level requires a $3,000 contribution.
• Ability to host a Sponsored Presentation
• Company Name listed in the printed Program
• Company Name listed in pre-meeting promotional pieces
• Company Name on the Meeting website
• Verbal acknowledgment at the Plenary Lecture
• Verbal acknowledgment at the Awards Ceremony
• Acknowledgment on a meter board at the Annual Meeting
• Sponsor badge ribbon/s for your representatives
Sponsorship at this level is up to a $2,999 contribution.
• Ability to host a Sponsored Presentation (contribution of $2,500 or higher)
• Company Name listed in the printed Program
• Company Name listed in pre-meeting promotional pieces
• Company Name on the Meeting Website
• Acknowledgment on a meter board at the Annual Meeting
• Sponsor badge ribbon/s for your representatives
Social Event Sponsorship Opportunities
If your company is interested in sponsoring the 2019 Social Event, please contact Krystle Correll. There are multiple sponsor levels, however our Diamond Level opportunities are limited.